Vertical ridge augmentation using an equine bone and collagen block infused with recombinant human platelet-derived growth factor-BB: a randomized single-masked histologic study in non-human primates.
BACKGROUND
This study tests the effectiveness of hydroxyapatite and collagen bone blocks of equine origin (eHAC), infused with recombinant human platelet-derived growth factor-BB (rhPDGF-BB), to augment localized posterior mandibular defects in non-human primates (Papio hamadryas).


METHODS
Bilateral critical-sized defects simulating severe atrophy were created at the time of the posterior teeth extraction. Test and control blocks (without growth factor) were randomly grafted into the respective sites in each non-human primate.


RESULTS
All sites exhibited vertical ridge augmentation, with physiologic hard- and soft-tissue integration of the blocks when clinical and histologic examinations were done at 4 months after the vertical ridge augmentation procedure. There was a clear, although non-significant, tendency to increased regeneration in the test sites. As in the first two preclinical studies in this series using canines, experimental eHAC blocks infused with rhPDGF-BB proved to be a predictable and technically viable method to predictably regenerate bone and soft tissue in critical-sized defects.


CONCLUSIONS
This investigation supplies additional evidence that eHAC blocks infused with rhPDGF-BB growth factor is a predictable and technically feasible option for vertical augmentation of severely resorbed ridges.
Department of Oral Medicine, Infection, and Immunity, Division of Periodontics, Harvard School of Dental Medicine, Boston, MA 02115, USA. nevinsperimp@aol.com
Myron
M
Nevins
Khalid
K
Al Hezaimi
Peter
P
Schupbach
Nadeem
N
Karimbux
David M
DM
Kim
D016301:Alveolar Bone Loss / Q000601:surgery; D000540:Alveolar Ridge Augmentation / Q000379:methods*; D043925:Angiogenesis Inducing Agents / Q000627:therapeutic use*; D000818:Animals; D000077214:Becaplermin; D001672:Biocompatible Materials / Q000627:therapeutic use; D001853:Bone Marrow / Q000473:pathology; D001861:Bone Regeneration / Q000502:physiology; D016723:Bone Remodeling / Q000502:physiology; D016025:Bone Transplantation / Q000379:methods*; D003094:Collagen / Q000627:therapeutic use*; D004396:Coloring Agents; D017886:Durapatite / Q000627:therapeutic use; D005240:Feasibility Studies; D016557:Guided Tissue Regeneration, Periodontal / Q000379:methods; D006736:Horses; D006801:Humans; D008334:Mandible / Q000601:surgery; D010012:Osteogenesis / Q000502:physiology; D048529:Papio hamadryas; D020574:Proto-Oncogene Proteins c-sis / Q000627:therapeutic use*; D011754:Pyronine; D011897:Random Allocation; D011994:Recombinant Proteins; D016037:Single-Blind Method; D013997:Time Factors; D014048:Tolonium Chloride
D043925:Angiogenesis Inducing Agents; D001672:Biocompatible Materials; D004396:Coloring Agents; D020574:Proto-Oncogene Proteins c-sis; D011994:Recombinant Proteins; D014048:Tolonium Chloride; D000077214:Becaplermin; D003094:Collagen; D017886:Durapatite; D011754:Pyronine